frontiers | Frontiers in Pharmacology

TYPE Correction
PUBLISHED 12 January 2023
DOI 10.3389/fphar.2022.1129448

OPEN ACCESS

EDITED AND REVIEWED BY
Ke-Wu Zeng,
Health Science Centre, Peking University, China

*CORRESPONDENCE
Jian-xiong Ma,
reproductivedcf@sina.com

†These authors have contributed equally to this work

SPECIALTY SECTION
This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

RECEIVED 22 December 2022
ACCEPTED 28 December 2022
PUBLISHED 12 January 2023

CITATION
Chen W-q, Ding C-f, Yu J, Wang C-y, Wan L-y, Hu H-m and Ma J-x (2023), Corrigendum: Wuzi Yanzong pill—Based on network pharmacology and *In Vivo* evidence—Protects against spermatogenesis disorder *via* the regulation of the apoptosis pathway. *Front. Pharmacol.* 13:1129448. doi: 10.3389/fphar.2022.1129448

Corrigendum: Wuzi Yanzong pill—Based on network pharmacology and *In Vivo* evidence—Protects against spermatogenesis disorder *via* the regulation of the apoptosis pathway

Wang-qiang Chen[1†], Cai-fei Ding[1†], Jia Yu[1], Chen-ye Wang[1], Ling-yi Wan[1], Hui-min Hu[1] and Jian-xiong Ma[1,2,3*]

[1]Department of Reproductive Medicine, Zhejiang Provincial Integrated Chinese and Western Medicine Hospital, Hangzhou, China, [2]The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China, [3]Department of Andrology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China

KEYWORDS

Wuzi Yanzong pill, spermatogenesis disorder, network pharmacology, bioactive compounds, hub targets, apoptosis pathway

A Corrigendum on
Wuzi Yanzong pill—Based on network pharmacology and *In Vivo* evidence—Protects against spermatogenesis disorder *via* the regulation of the apoptosis pathway

by Chen W, Ding C, Yu J, Wang C, Wan L, Hu H and Ma J (2020). Front. Pharmacol. 11:592827. doi: 10.3389/fphar.2020.592827

In the published article, there was an error in Figures 4, 6 as published. The images in Figure 4D and the immunohistochemical staining of Bcl-XL in Figure 6 were mistakenly swapped. The corrected Figures 4, 6 appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

10.3389/fphar.2022.1129448



FIGURE 4
Compounds identification and the effect of the WZYZP on the experimental spermatogenesis disorder model rats. **(A)** The phytochemical compositions identification in the WZYZP by UHPLC-Q-TOF/MS in the positive ion mode and negative ion mode. **(B)** Effect of the WZYZP on sperm counts and motility. **(C)** Effect of WZYZP on serum hormone levels of T, FSH levels were detected with an ELISA assay. **(D)** HE staining to evaluate the effect of the WZYZP on rat testes histological changes. Above, magnification ×200, 400. **(E)** TUNEL staining for the evaluation of cell apoptosis. Above, magnification ×200. #$p < .05$ vs. Model group, ##$p < .01$ vs. Model group.



FIGURE 6
Effect of the WZYZP on the expression levels of Bcl-XL and Bax in testes tissues. The expression levels of Bcl-XL and Bax in the testes were determined by immunohistochemistry analysis. Above, magnification ×200, 400. #$p < .05$ vs. Model group, ##$p < .01$ vs. Model group.

Publisher's note